Nanjing Well Pharmaceutical Group Co.,Ltd.

SHSE:603351 Stock Report

Market Cap: CN¥3.3b

Nanjing Well Pharmaceutical GroupLtd Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Renrong Wu

Chief executive officer

CN¥990.7k

Total compensation

CEO salary percentagen/a
CEO tenure4.7yrs
CEO ownership13.7%
Management average tenureno data
Board average tenure4.7yrs

Recent management updates

Recent updates

Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Earnings Are Of Questionable Quality

Aug 26
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Earnings Are Of Questionable Quality

Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Upcoming Dividend Will Be Larger Than Last Year's

Jun 07
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Upcoming Dividend Will Be Larger Than Last Year's

Little Excitement Around Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Earnings

Jun 06
Little Excitement Around Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Earnings

CEO

Renrong Wu (61 yo)

4.7yrs

Tenure

CN¥990,700

Compensation

Mr. Renrong Wu is Chairman, Director & CEO of Nanjing Well Pharmaceutical Group Co.,Ltd. from April 08, 2020. He joined the Nanjing Well Pharmaceutical Group Co.,Ltd.in February 2000.

Board Members

NamePositionTenureCompensationOwnership
Renrong Wu
Chairman & CEO4.7yrsCN¥990.70k13.68%
CN¥ 448.0m
Zhengsong Gao
Director4.7yrsCN¥825.60k10.42%
CN¥ 341.4m
Xinguo Chen
Director & VP4.7yrsCN¥825.60k10.42%
CN¥ 341.4m
Yamei Guan
Independent Director1.6yrsCN¥49.70kno data
Rongwen Wu
Chairman of the Supervisory Board4.7yrsno data2.2%
CN¥ 72.1m

4.7yrs

Average Tenure

58yo

Average Age

Experienced Board: 603351's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 04:16
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nanjing Well Pharmaceutical Group Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution